6 results about "Peroxisome proliferator" patented technology

The present invention relates to the use of skin benefit agents for enhancing the overnight repair function of skin, wherein the skin benefit agents are selected from the group consisting of: borage oil, farnesol, activators of the peroxisome proliferator-activated receptors, and mixtures thereof; and wherein the skin benefit agents are applied to the skin from about 5 pm to about 12 am at the end of the day.

The present invention is directed to an isotropic wash composition. The composition is stable, comprises alfa olefin sulfonate and a co-anionic surfactant. The composition comprises an amphoteric surfactant, low salt content and can comprise a peroxisome proliferator-activated receptor (PPAR) agonist.

Microparticulate (MP) formulations formed from one or more poly(hydroxyacid) polymers having a molecular weight ranging from 5kD to 60kD, and one or more active agents are injected into the eye of a subject to address eye disorders. The MP formulations assure high drug loading and extended delivery of the active agent of six to twelve months. The active agents may include peroxisome proliferator-activated receptor alpha (PPARα) signaling agonists such as PPARα agonist A190 (IUPAC name 3-((4-((4-fluorobenzyl)oxy)- 3- methylbenzyl)amino)benzoic acid). The formulations have therapeutic and protective effects against retinal degeneration diseases such as age-related macular degeneration (AMD), but may also be used for treating or relieving the symptoms of retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity (ROP), diabetic retinopathy (DR), and diabetic macular edema (DME).

The present invention is directed to an isotropic and pearlescent wash composition. The composition is stable, comprises pearlescent agent and peroxisome proliferator-activated receptor (PPAR) agonist. The pearlescent agent is homogeneously dispersed when the wash composition is substantially free of polymeric thickening agent and suspending agent.

Provided are methods of treating subjects in need of an anti-fibroblast growth factor receptor 3 (anti-FGFR3) therapy. The methods comprise administering to the subjects a therapeutically effective amount of a peroxisome proliferator-activated receptor (PPAR) alpha agonist in combination with the anti-FGFR3 therapy. The methods can comprise administering to the subject a therapeutically effective amount of PPAR alpha agonist and a bile acid sequestrant. Also provided are compositions comprising an FGFR3 inhibitor, a PPAR alpha agonist, and, optionally, a bile acid sequestrant. The methods attenuate the dysregulation of bile acid biosynthesis caused by FGFR3 inhibition with anti-FGFR3 therapies. The methods reduce the severity and / or incidence of adverse events associated with anti-FGFR3 therapies.

The present invention relates to methods for treating an ophthalmic condition in a defined patient in need of treatment thereof. The methods comprise inducing the activity of peroxisome proliferator–activated receptor gamma coactivator-1 alpha (PGC1α) in a defined patient that needs treatment of an ophthalmic condition. The defined patient in these methods has been previously identified as having reduced carboxylesterase 1 (CES1) activity, compared to normal activity levels of CES1.